Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Tacrolimus

Tacrolimus Reactions 1704, p354 - 2 Jun 2018 Symmetric drug-related intertriginous and flexural exanthema: case report A 41-year-old man developed symmetric drug-related intertriginous and flexural exanthema (SDRIFE) during treatment with tacrolimus as an immunosuppressant therapy [route and duration of treatment to reaction onset not stated]. The man had undergone a kidney and liver transplantation three years ago. Following the transplant, he started receiving tacrolimus 7mg daily. Nine months before presentation, he had developed a chronic, erythematous, itchy, papular eruption, which symmetrically affected his legs and arms including the groins, axillae, flexural folds, neck and gluteal region. He did not show any other signs or symptoms. A skin biopsy revealed epidermal spongiosis and a perivascular superficial and dermo-epidermal infiltrate, which were composed of histiocytes, lymphocytes and some eosinophils without the involvement of basal layer. Drug eruption and allergic contact dermatitis were suspected and patch tests were planned. The patch testing included tacrolimus ointment [Tarfic] at two different concentrations of 0.1% and 0.03% respectively, with occlusion of two days. On day four, his test was positive for cobalt, nickel and the tacrolimus ointment 0.1%. A diagnosis of the SDRIFE was made. The man started receiving corrective treatment with propranolol. His serum tacrolimus http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Tacrolimus

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Download PDF
1 page

Tacrolimus

Abstract

Reactions 1704, p354 - 2 Jun 2018 Symmetric drug-related intertriginous and flexural exanthema: case report A 41-year-old man developed symmetric drug-related intertriginous and flexural exanthema (SDRIFE) during treatment with tacrolimus as an immunosuppressant therapy [route and duration of treatment to reaction onset not stated]. The man had undergone a kidney and liver transplantation three years ago. Following the transplant, he started receiving tacrolimus 7mg daily. Nine months before...
Loading next page...
 
/lp/springer_journal/tacrolimus-xgzXk341dZ

References (1)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46997-x
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p354 - 2 Jun 2018 Symmetric drug-related intertriginous and flexural exanthema: case report A 41-year-old man developed symmetric drug-related intertriginous and flexural exanthema (SDRIFE) during treatment with tacrolimus as an immunosuppressant therapy [route and duration of treatment to reaction onset not stated]. The man had undergone a kidney and liver transplantation three years ago. Following the transplant, he started receiving tacrolimus 7mg daily. Nine months before presentation, he had developed a chronic, erythematous, itchy, papular eruption, which symmetrically affected his legs and arms including the groins, axillae, flexural folds, neck and gluteal region. He did not show any other signs or symptoms. A skin biopsy revealed epidermal spongiosis and a perivascular superficial and dermo-epidermal infiltrate, which were composed of histiocytes, lymphocytes and some eosinophils without the involvement of basal layer. Drug eruption and allergic contact dermatitis were suspected and patch tests were planned. The patch testing included tacrolimus ointment [Tarfic] at two different concentrations of 0.1% and 0.03% respectively, with occlusion of two days. On day four, his test was positive for cobalt, nickel and the tacrolimus ointment 0.1%. A diagnosis of the SDRIFE was made. The man started receiving corrective treatment with propranolol. His serum tacrolimus

Journal

Reactions Weekly – Springer Journals

Published: Jun 2, 2018

There are no references for this article.